Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2296MR)

This product GTTS-WQ2296MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2296MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10256MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ4299MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ14235MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ14288MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ2596MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ1165MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ2637MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ2387MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW